Morphosys Ag (MOR.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2009 | |
| Cash Flows From Operating Activities | |
| Accounts receivable | -1,555 |
| Other Working Capital | 1,711 |
| Other Operating Activity | -1,827 |
| Operating Cash Flow | $-1,670 |
| Cash Flows From Investing Activities | |
| PPE Investments | -159 |
| Sale Of Investment | 7,346 |
| Purchase Sale Intangibles | -131 |
| Investing Cash Flow | $7,055 |
| Cash Flows From Financing Activities | |
| Debt Issued | 61 |
| Other Financing Activity | -128 |
| Financing Cash Flow | $-67 |
| Exchange Rate Effect | -18 |
| Beginning Cash Position | 40,114 |
| End Cash Position | 45,414 |
| Net Cash Flow | $5,318 |
| Free Cash Flow | |
| Operating Cash Flow | -1,670 |
| Capital Expenditure | -291 |
| Free Cash Flow | -1,962 |